Personal information

Parkinson, Molecular Biology, Behavioural Pharmacology, Preclinical Drug Discovery, Neuroscience
India

Biography

Neuroscience: MicroRNAs: Theranostic: Parkinson's Disease: Nose to brain delivery
We are trying to understand the α-synuclein dysregulation at post-transcriptional (miRNA’s) and post-translational levels (Phosphorylation), leading to its overexpression and transition to toxic oligomeric form in PD. A multidisciplinary approach is employed to investigate the cellular and molecular mechanism underlying the pathogenic degeneration of specific neuronal populations in the brain. In addition, the pharmacological screening of novel molecules isolated from plant sources or synthetic congeners, and targeted drug delivery systems for their neuroprotective and neuronal regeneration properties carried out using cellular and animal models.

Activities

Employment (2)

National Institute of Pharmaceutical Education and Research: HYDERABAD, TELANGANA, IN

2019-03-04 to present | Assistant Professor (Pharmacology and Toxicology)
Employment
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Padmashree Dr D Y Patil Institute of Pharmaceutical Sciences and Research: Pune, Maharashtra, IN

2017-08-04 to 2019-02-28 | Assistant Professor (Pharmacology)
Employment
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Education and qualifications (2)

Institute of Chemical Technology: Mumbai, Maharashtra, IN

2012-12-10 to 2017-02-08 | PhD (TECHNOLOGY)-PHARMACOLOGY (PHARMACEUTICAL SCIENCES )
Education
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Institute of Chemical Technology: Mumbai, Maharashtra, IN

2010-08-23 to 2012-06-30 | MASTER OF PHARMACY (PHARMACEUTICAL SCIENCES )
Education
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Professional activities (8)

Society for Neuroscience: WA, WA, US

Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

International Society for Pediatric and Adolescent Diabetes: Berlin, Berlin, DE

Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

International Society for Neurochemistry: Geneva, CH

Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

International Parkinson and Movement Disorder Society: WI, WI, US

Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Indian Academy of Neurosciences: Lucknow, IN

Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Federation of European Neuroscience Societies: Brussels, BE

Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Association of Physiologist and Pharmacologist of India: India, IN

2022-10-19 to present | Life member
Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Society for Neurochemistry India: Hyderabad, India, IN

2022-09-23 to present | Life member
Membership
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Funding (7)

To Develop Parkinson’s Disease and a Glioblastoma brain tumor model in rodents using Stereotaxic

2022-03 to 2022-09 | Contract
Sai Life Sciences Ltd. (Hyderabad, Telangana, IN)
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Development of Novel Eye Drops of fixed-dose combination for Effective Ocular Delivery

2021-09 to 2024-09 | Grant
Department of Science and Technology (New Delhi, DELHI, IN)
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Extraction, Charaterization and Pre-clinical Pharmacodynamics Assesmant of Promising Unani-Medicines against Hepatic Disease

2021-06 to 2024-06 | Grant
Central Council for Research in Homeopathy, Ministry of AYUSH, Government of India (Delhi, DELHI, IN)
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

To study the efficacy of therapeutic plant molecule in animal models to treat Chronic Obstructive Pulmonary Disease (COPD) by the lung regeneration/repair process

2021-05 to 2022-08 | Contract
NBI Biosciences Pvt. Ltd (Gurgaon, Delhi, IN)
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Design, synthesis and biological evaluation of new GSK3 beta inhibitors as promising therapeutic agents for treating Traumatic brain injury and consequent neuronal degenerative diseases

2020-12 to 2023-12 | Grant
Indian Council of Medical Research (New Delhi, DELHI, IN)
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Development of andrographolide-cyclodexrtin inclusion complex and evaluation of its oral bioavailability, acute and sub-acute toxicity in experimental animals

2020-05 to 2021-05 | Contract
M/s Ambe Phytoextracts Private Limited (Delhi, India, IN)
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Category 1B: Research Supplies for use in the applicant’s home laboratory) to the Committee for Aid and Education in Neurochemistry

2019-04 to 2020-04 | Grant
International Society for Neurochemistry (Genewa, Switzerland, CH)
Source: Self-asserted source
DHARMENDRA KUMAR KHATRI

Peer review (97 reviews for 46 publications/grants)

Review activity for ACS chemical neuroscience. (1)
Review activity for Ageing research reviews. (1)
Review activity for Behavioural brain research. (2)
Review activity for Biochemical and biophysical research communications. (1)
Review activity for Biochimica et biophysica acta. (1)
Review activity for Bioengineered. (1)
Review activity for Biomedical engineering and computational biology. (1)
Review activity for Brain and behavior. (6)
Review activity for Brain research. (2)
Review activity for Cellular signalling. (2)
Review activity for Clinical and experimental pharmacology & physiology. (2)
Review activity for Diabetes, metabolic syndrome and obesity. (1)
Review activity for Ecotoxicology and environmental safety. (2)
Review activity for Epigenetics. (2)
Review activity for Epigenomics (1)
Review activity for European journal of neuroscience (2)
Review activity for Experimental neurology. (3)
Review activity for Expert opinion on drug delivery (3)
Review activity for Expert opinion on pharmacotherapy (2)
Review activity for Fitoterapia. (1)
Review activity for Free radical biology & medicine. (2)
Review activity for Future medicinal chemistry. (1)
Review activity for Gut microbes. (1)
Review activity for Heliyon. (5)
Review activity for Human gene. (3)
Review activity for IBRO neuroscience reports. (1)
Review activity for Indian Journal of Clinical Biochemistry. (2)
Review activity for Indian journal of clinical biochemistry. (1)
Review activity for International journal of general medicine (1)
Review activity for International Journal of Neuroscience (5)
Review activity for iScience. (3)
Review activity for Journal of biochemical and molecular toxicology. (2)
Review activity for Journal of ethnopharmacology. (1)
Review activity for Journal of inflammation research (1)
Review activity for Life sciences. (1)
Review activity for Molecular neurobiology. (9)
Review activity for Molecular neurobiology. (8)
Review activity for Nanomedicine. (1)
Review activity for Neuropharmacology. (2)
Review activity for Neuropsychiatric disease and treatment (1)
Review activity for Neuroscience insights. (2)
Review activity for Neurotoxicology. (1)
Review activity for Psychopharmacologia. (1)
Review activity for Psychopharmacology. (1)
Review activity for Therapeutic delivery. (1)
Review activity for Trends in food science & technology. (3)